AU3822993A - The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds - Google Patents

The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds

Info

Publication number
AU3822993A
AU3822993A AU38229/93A AU3822993A AU3822993A AU 3822993 A AU3822993 A AU 3822993A AU 38229/93 A AU38229/93 A AU 38229/93A AU 3822993 A AU3822993 A AU 3822993A AU 3822993 A AU3822993 A AU 3822993A
Authority
AU
Australia
Prior art keywords
inflammations
wounds
inhibitors
treatment
plasminogen activators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38229/93A
Inventor
Gerhard Dickneite
Eric-Paul Paques
Jurgen Romisch
Eckhard Schuler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of AU3822993A publication Critical patent/AU3822993A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU38229/93A 1992-04-30 1993-04-29 The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds Abandoned AU3822993A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4214215A DE4214215A1 (en) 1992-04-30 1992-04-30 USE OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATING INFLAMMATION
DE4214215 1992-04-30

Publications (1)

Publication Number Publication Date
AU3822993A true AU3822993A (en) 1993-11-04

Family

ID=6457814

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38229/93A Abandoned AU3822993A (en) 1992-04-30 1993-04-29 The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds

Country Status (16)

Country Link
EP (1) EP0567816A1 (en)
JP (1) JPH069425A (en)
KR (1) KR930021179A (en)
CN (1) CN1080873A (en)
AU (1) AU3822993A (en)
CA (1) CA2095207A1 (en)
CZ (1) CZ76893A3 (en)
DE (1) DE4214215A1 (en)
HU (1) HUT65755A (en)
IL (1) IL105521A0 (en)
MX (1) MX9302519A (en)
NO (1) NO931561L (en)
PL (1) PL298748A1 (en)
SK (1) SK41593A3 (en)
UY (1) UY23572A1 (en)
ZA (1) ZA933023B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049887A1 (en) * 1998-04-01 1999-10-07 Biotech Australia Pty. Limited Use of protease inhibitors for treating skin wounds

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
GB2271507A (en) * 1992-09-04 1994-04-20 Summit Technology Ireland Bv Compositions containing plasmin activity inhibitors
DK1159974T3 (en) 1993-07-19 2007-11-26 Angiotech Pharm Inc Antiangiogenic compositions containing taxol and a non-biodegradable carrier and their use
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5939525A (en) * 1995-03-27 1999-08-17 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
MXPA01011025A (en) 1999-04-29 2002-11-07 Ista Pharmaceuticals Inc Biochemical methods that eliminate corneal scars, opacification and haze.
US6156373A (en) * 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
JP3690720B2 (en) 1999-09-14 2005-08-31 インターナショナル・ビジネス・マシーンズ・コーポレーション Client server system, object pooling method, and storage medium
AU1123001A (en) 1999-10-27 2001-05-08 Alexandra Lucas Compositions and methods for preventing and treating transplant rejection
JP2001247458A (en) * 2000-03-08 2001-09-11 Hamari Chemicals Ltd Therapeutic agent for diabetes comprising zinc tranexmate compound
ATE453402T1 (en) 2000-09-29 2010-01-15 Viron Therapeutics Inc USE OF SERP-1 IN COMBINATION WITH AN IMMUNOSUPPRESSOR TO TREAT ARTHRITIS
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
JP2004511297A (en) 2000-10-16 2004-04-15 コナー　メドシステムズ，　インコーポレイテッド Expandable medical device for delivering beneficial drugs
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
AT500019B1 (en) * 2001-06-27 2007-06-15 Inst Gefaessbiologie Und Throm USE IN VITRO OF THE TRANSCRIPTION FACTOR NAK-1 OR NAK-1 REGULATED GENES FOR THE DIAGNOSIS OF INFLAMMATORY AND MALIGNIC DISEASES
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
CN101977626A (en) * 2008-01-21 2011-02-16 德莫迪斯公司 Use of serine protease inhibitors in the treatment of skin diseases
TWI763960B (en) * 2017-12-15 2022-05-11 大陸商深圳瑞健生命科學研究院有限公司 Method and medicine for preventing or treating osteoarthritis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3829523A1 (en) * 1988-08-31 1990-03-01 Behringwerke Ag USE OF PLASMINOGEN ACTIVATOR INHIBITOR (PAI-2) FOR IMMUNE SUPPRESSION
DE69031271T2 (en) * 1989-12-20 1998-02-26 Biotech Australia Pty Ltd Variants of PAI-2
EP0451130A3 (en) * 1990-04-05 1992-08-05 Baltimore Biotech, Inc. Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049887A1 (en) * 1998-04-01 1999-10-07 Biotech Australia Pty. Limited Use of protease inhibitors for treating skin wounds

Also Published As

Publication number Publication date
HUT65755A (en) 1994-07-28
EP0567816A1 (en) 1993-11-03
CZ76893A3 (en) 1994-01-19
CN1080873A (en) 1994-01-19
KR930021179A (en) 1993-11-22
PL298748A1 (en) 1993-12-27
SK41593A3 (en) 1993-11-10
IL105521A0 (en) 1993-08-18
DE4214215A1 (en) 1993-11-04
CA2095207A1 (en) 1993-10-31
MX9302519A (en) 1993-10-01
JPH069425A (en) 1994-01-18
NO931561L (en) 1993-11-01
HU9301272D0 (en) 1993-07-28
ZA933023B (en) 1994-10-31
NO931561D0 (en) 1993-04-29
UY23572A1 (en) 1993-05-04

Similar Documents

Publication Publication Date Title
AU3822993A (en) The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds
AU2956492A (en) Antibacterial agent and treatment of article therewith
HU9303218D0 (en) Application of atp-depended protease and its inhibitor for treatment of cachexy and amyotrophia
AU673703B2 (en) Injector and use of the same
AU5590596A (en) Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
AU4267293A (en) Use of MMP inhibitors
AU1515295A (en) Inhibitors of urokinase plasminogen activator
AU5748194A (en) Mannitol derivatives and their use as inhibitors of aspartyl protease
AU4859793A (en) Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation
AU6797094A (en) Cosmetic treatment of substrates
AU4214193A (en) Bioadhesive treatment compositions and method of use
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
AU3959193A (en) Heterocyclic compounds and their use in the treatment of type II-diabetes
AU4098393A (en) Laminate and use of the same
AU3107795A (en) Inhibitors of the benzamidine type
AU4630693A (en) Methods for treating non-suturable wounds by use of cyanoacrylate adhesives
AU5960994A (en) Surgical cutting block and method of use
AU3099997A (en) The use of tcet in the prophylaxis and treatment of allergies
AU1438295A (en) Method for treatment of papulo-pustules and comedones of the skin
AU4135493A (en) Inhibitors of HIV protease useful for the treatment of AIDS
AU5252993A (en) Inhibitors of HIV protease useful for the treatment of AIDS
AU7065694A (en) Catheter and method of use thereof
AU4220193A (en) Deazaaminopterins for treatment of inflammation
AU2843397A (en) Agent for prophylaxis and treatment of disturbance of visual function
AU675090B2 (en) The use of thrombin inhibitors for the inhibition of ocular fibrin formation